|
||
Articles |

CTL by TL Antigen Expressed in the Thymus


Department of Dermatology, Nagoya City University School of Medicine, Mizuho-ku, Nagoya 467, Japan; and
Department of Chemical Hygiene and Nutrition, Faculty of Pharmaceutical Sciences, Nagoya City University, Mizuho-ku, Nagoya 467, Japan
| Abstract |
|---|
|
|
|---|

, whereas almost all those from C3H expressed TCR
β. The MLC from Tg.Tlaa-3-2 and C3H demonstrated high CTL activity against TL, while those from Tg.Tlaa-3-1 had little or none. The generation of 
CTL recognizing TL in Tg.Tlaa-3-2, but not C3H mice, was confirmed by the establishment of CTL clones. A total of 14 
CTL clones were established from Tg.Tlaa-3-2, whereas none were obtained from C3H. Of the 14 
CTL clones, 8 were CD8+ and 6 were CD4–CD8– double negative. The CTL activity of all these clones was TL specific and inhibited by anti-TL, but not by anti-H-2 antibodies, demonstrating that they recognize TL directly without antigen presentation by H-2. The CTL activity was blocked by antibodies to TCR
and CD3, and also by antibodies to CD8
and CD8β in CD8+ clones, showing that the activity was mediated by TCR
and coreceptors. The thymic origin of these 
CTL clones was indicated by the expression of Thy-1 and Ly-1 (CD5), and also CD8
β heterodimers in CD8+ clones on their surfaces and by the usage of TCR V
4 chains in 12 of the 14 clones. Taken together, these results suggest that Tlaa-3-TL antigen expressed in the thymus engages in positive selection of a sizable population of 
T cells.
Mice have at least 30–40 genes called "nonclassical" MHC class I or MHC class "Ib" genes mainly mapping to three chromosomal regions within the murine MHC: H-2Q, T, and M (1, 2). Recent studies have demonstrated that some of the proteins encoded by these genes are related to the classical MHC class I molecules in structure and in function, presenting antigens to
TL antigens belong to the family of nonclassical MHC class I antigens (6). At least one gene coding for a TL antigen is present in all mouse strains so far tested, and two or more have been found in some strains; T3b has been found in C57BL/6 (B6)1, T3k in C3H/He (C3H), T3d and T18d in BALB/c and Tlaa-1, Tlaa-2 and Tlaa-3 in A strain. What makes TL distinct from other MHC class I antigens is their unique expression profile (6–10). TL antigens are expressed in epithelial cells of the small and large intestines in all mouse strains. Certain strains such as A and BALB/c also express TL on normal thymocytes, while others such as B6 and C3H do not. Even in B6 and C3H mice, however, malignant transformation of T cell causes TL to be expressed.
The structures of TL genes and products are very similar to those of classical MHC class I genes and products (6). However, until our recent study, TL had not been shown to behave like MHC class I antigens in terms of histocompatibility antigen. We derived H-2Kb/T3b transgenic mice expressing the TL antigen ubiquitously under the action of an H-2Kb promoter (11). By transplanting their skin onto C3H mice, the background strain, we demonstrated that TL can serve as a transplantation antigen and elicit TCR
We have derived another pair of transgenic mouse strains with Tlaa-3 of A strain origin. One of these, Tg.Tlaa-3-1, expresses large amounts of TL antigen on thymocytes and has a small thymus consisting mainly of L3T4(CD4)–Lyt2(CD8)– double negative (DN) cells of
β or 
T cells (reviewed in reference 2), while others have completely different functions such as that acting as an Fc receptor for IgG (FcRn) (3). The idea that some nonclassical class I molecules might function as restriction elements for 
T cells has been suggested by the distinctive tissue distribution and limited V gene usage of 
T cells. Indeed, several studies have shown that 
T cells recognize nonclassical class I molecules encoded by genes located within the Q or T regions (reviewed in references 4, 5).
β CD8+ CTL response (12). Furthermore, we showed that this CTL response is TL restricted so that CTL directly recognizes TL or a complex of TL plus antigenic molecules without any requirement for antigen presentation by classical MHC class I molecules. The results suggested the possibility that TL can serve as an antigen presenting molecule, similar to classical MHC class I antigens. 
lineage, and it develops a high incidence of T cell lymphomas, suggesting that TL plays a critical role in T cell development in the thymus, especially of the 
T cell lineage (13). However, the other Tlaa-3 transgenic strain, Tg.Tlaa-3-2, demonstrates no obvious abnormalities in thymic development and does not develop T cell lymphomas (11). In the present study, to define the role of TL antigens expressed in the thymus, we generated and characterized TL-restricted CTL responses in Tg.Tlaa-3-1 and Tg.Tlaa-3-2 mice and made a comparison with those in C3H strain.
![]()
Materials and Methods
Top
Abstract
Materials and Methods
Results
Discussion
References
TL Genes.
Three TL genes, T3b of B6 (14), Tlaa-3 of A strain (15), and T3k of C3H (EMBL/GenBank/DDBJ accession No. D86082) were involved in this study. The DNA sequences of their coding regions and deduced amino acid sequences are very similar to each other and >90% of their nucleotides and amino acids are identical. Furthermore, all three TL molecules have identical amino acid sequences in the putative peptide binding region (PBR) which determines the binding specificity of MHC class I molecules to antigenic peptides and to TCR. Outside PBR, however, there are differences as shown in Fig. 1.
|
Antibodies.
The following mAbs and one conventional antibody (cAb) were developed in our laboratory, provided by various scientists, or purchased: Rat mAb to Lyt-2 (53-6.7; Dr. N. Shinohara, Mitsubishi Kasei Institute for Life Science, Machida, Japan [16]), rat mAb to L3T4 (GK1.5; Dr. N. Shinohara [17]), hamster mAb to TCR
β (H57-597; Dr. R.T. Kubo, National Jewish Center for Immunology and Respiratory Medicine, Denver, CO [18]), hamster mAb to TCR
(3A10; Dr. S. Tonegawa, Massachusetts Institute of Technology, Cambridge, MA [19]), hamster mAb to TCR
(GL3; Cedarlane Labs. Ltd., Hornby, Ontario, Canada), hamster mAb to V
4 (UC3-10A6; PharMingen, San Diego, CA), hamster mAb to CD3 (145-2C11; Dr. J.A. Bluestone, The University of Chicago, Chicago, IL [20]), mouse mAb to TL.2 (TT213 [12]), mouse mAb to Ly-1.1, mouse mAb to Lyt-3.2 (ID9P35), rat mAb to Thy-1.2 (Becton Dickinson, Immunocytometry Sys., Mountain View, CA), and cAb to H-2k ([B6 x DBA/2] anti-C3H mammary tumor, MM48).
Flow Cytometric Analysis.
Flow cytometric analysis was performed with a FACScan®. For secondary reagents, PE-conjugated streptavidin (Biomeda Corp., Foster City, CA), FITC-labeled anti– hamster Ig (CALTAG Labs., South San Francisco, CA), anti–rat Ig (Tago Inc., Burlingame, CA), or anti–mouse Ig (DAKOPATTS, Glostrup, Denmark) were used.
Skin Grafts.
Female Tg.Tlaa-3-1, Tg.Tlaa-3-2 and C3H mice (6–10-wk-old) received full-thickness sections of skin (1-cm disks) from the abdomens of Tg.Con.3-1 mice onto their backs. Plaster casts were removed on day 10.
Establishment and Maintenance of CTL Bulk Cultures and Clones.
The methods for induction of CTL and assays for their cytotoxic activity have been described previously (12). Briefly, 4–8 wk after the rejection of grafted skin, spleen cells (5 x 107) from the recipient mice were cultured with 5 x 107 irradiated (2,000 R) Tg.Con.3-1 spleen cells for 5 d. The cells were used as effector cells in CTL assays and maintained as CTL bulk cultures by weekly restimulation with irradiated Tg.Con.3-1 spleen cells in the presence of human recombinant IL-2 (Takeda Chemical Industries Ltd., Osaka, Japan) at a concentration of 5 ng/ml. For CTL assays, 51Cr-labeled target cells (2 x 104) were incubated with various numbers of effector cells. For the blocking test of CTL activity by antibodies, serially diluted antibodies were added to mixtures of effector cells and labeled target cells. After incubation for 3 h at 37°C, the supernatants were harvested using a Supernatant Collection System (Skatron Inc., Sterling, VA) for measurement of 51Cr release. The percent specific lysis was calculated using the following equation: 100 x (a – b/c – b), where a is the radioactivity in the supernatant of target cells mixed with effector cells, b is the radioactivity in the supernatant of target cells incubated without effector cells, and c is the radioactivity in the supernatant after complete lysis of target cells with 2% Triton X-100.
For cloning, cells were diluted to 1–100 cells/well and cultured with irradiated Tg.Con.3-1 spleen cells in the presence of IL-2 in 96-well plates. After 10–14 d, the cytotoxity of clonally growing cells was tested. Established clones were maintained by weekly stimulation and their activity was tested as described above.
Target Cells.
Con A–stimulated spleen cells of Tg.Con.3-1 and C3H were prepared as previously described (12). In addition to Con A–stimulated spleen cells, the following cells were used as targets for CTL assays, with the amounts of TL gene product on cell surfaces were estimated by flow cytometry with TT213 anti-TL mAb: Con A blasts of Tg.Con.3-1 (mean fluorescence intensity [MFI] of stained cells - MFI of unstained cells; 298.6, expressing T3b), C3H (0.1, TL–) and B6 (1.5, TL–), thymidine kinase-negative L-cells ([Ltk–], 4.0, TL–), and H-2Kb/T3b Ltk– transfectants (785.0, T3b), as well as ERLD (derived from B6, 253.5, T3b), RADA1 (derived from A strain, 178.9, Tlaa-1, -2, and -3), and ASL-1 (derived from A strain, 584.1, Tlaa-1, -2, and -3) leukemias maintained in vivo.
RNA Extraction and Reverse Transcription–PCR.
Total RNA was extracted from CTL clones using TRIzol Reagent (GIBCO BRL, Gaitherburg, MD). 10 µg of total RNA were reverse transcribed into first strand cDNA with 3 µg of random primers and 1,000 U of SuperScript II reverse transcriptase (RT) (GIBCO BRL). TCR
chains were amplified using V
-specific primers and a single common C
primer by the methods of Takagaki (21). The nomenclature of V
is according to Reilly et al. (22). The RT-PCR products were separated by agarose gel electrophoresis.
Nucleotide Sequencing of the V
-J
Junction.
PCR products were cloned into a T-tailed M13mp18 vector and sequenced by a cycle sequencing method using an automated DNA sequencer (model 373A; Applied Biosystems, Inc., Foster City, CA).
| Results |
|---|
|
|
|---|
β, while
15% from Tg.Tlaa-3-2 and >20% from Tg.Tlaa-3-1 expressed TCR
. In the 
T cell population derived from Tg.Tlaa-3-2, two thirds were L3T4–Lyt-2+, while approximately one third were L3T4–Lyt-2– double negative (DN), and very few were L3T4+Lyt-2– (Fig. 3 B). Of the 
T cells from Tg.Tlaa-3-1,
60% were DN, 25% were L3T4–Lyt-2+, and 15% were L3T4+Lyt-2– (data not shown). In the
β T cell population derived from both Tg.Tlaa-3-2 and C3H, >70% were L3T4–Lyt-2+ and the rest were L3T4+Lyt-2–. In contrast, the
β T cell population from Tg.Tlaa-3-1 consisted of
45% L3T4–Lyt-2+, 45% L3T4+Lyt-2– and 10% DN cells (data not shown).
|
|
β, CD3, and Lyt-2 antibodies but not by anti-TCR
or anti-L3T4. In the Tg.Tlaa-3-2 case, the CTL activity was blocked partially by anti-TCR
antibody, although not as strongly as shown by anti-TCR
β antibody, indicating a certain population of 
T cells. Together with the data from flow cytometric analysis, these results suggested that a small but significant proportion of CTL recognizing T3b-TL was skewed toward the 
lineage by the presence of Tlaa-3-TL antigen in the thymus.
|

CTL Clones.
, whereas all C3H CTL clones expressed TCR
β. Thus, establishment of the CTL clones indicated that 
CTL are induced characteristically in mice expressing TL in their thymus, confirming the results of bulk cultures.
Characteristics of the 
CTL Clones.
The three 
CTL clones described above were all Lyt-2+ (see below), although one third of 
T cells in bulk culture were DN as shown in Fig. 3 B. To test whether TL-reactive 
CTL clones with DN phenotype could be established, 11 additional 
CTL clones were derived from five Tg.Tlaa-3-2 mice. Thus, a total of 14 
CTL clones were characterized, as summarized in Table 1. Flow cytometric analysis showed eight to be Lyt-2+ and six to be DN. Lyt-2 is a CD8
chain, and in T cells of thymic origin, it forms a heterodimer with Lyt-3, a CD8β chain, while it forms an 
homodimer in those of intestinal epithelium (23). All Lyt-2+ 
CTL clones established in this study also expressed Lyt-3, indicating a thymic origin. In addition, a thymic origin of not only Lyt-2+, but also DN 
CTL clones, was indicated by the fact that all clones expressed Thy-1 and Ly-1 (CD5) on their cell surface (Table 1). Both antigens have been shown to be expressed on 
T cells of thymic origin, but not on those of extra-thymic origin (24, 25).
|

clones were examined for their cytotoxic activity against TL+ and TL– target cells. All lysed TL+ target cells including Con A blasts of Tg.Con.3-1 and RADA1, but not TL– cells including Con A blasts of C3H and B6. The results with CTL clones were essentially identical to those with the bulk culture. The 
CTL clones were also tested by antibody blocking for their target specificity and the expression of TCR and coreceptor molecules. The results are summarized in Table 1 and representative findings are shown in Fig. 5. Fig. 5, A and C, illustrate results for one of the Lyt-2+ 
CTL clones, KC4-4, and Fig. 5, B and D, for one of the DN 
CTL clones, KC8-3. The CTL activity of all these 
CTL clones was blocked by anti-TL antibodies, indicating the TL-specific CTL activity. Blocking by anti-TL antibodies but not by anti–H-2k antibody further indicated that these 
CTL clones directly recognize the TL molecule. The CTL activity was also blocked by anti-TCR
and CD3 antibodies. All Lyt-2+ 
CTL clones were blocked by anti–Lyt-2 and anti–Lyt-3 antibodies while all DN clones were not, confirming the results of flow cytometric analysis. Other than the Lyt-2 and Lyt-3 expression, these 14 
CTL clones showed no differences in their expression of adhesion, costimulatory, and accessory molecules; all 
CTL clones were positive for Pgp-1 (CD44), LFA-1 (CD11a), ICAM-1 (CD54), CD2, CD28, CTLA-4, and IL-2R
/β, and negative for L-selectin (CD62L), VLA-4
(CD49d), and HSA (data not shown).
|

CTL clones, their V
segment usage was determined. By RTPCR, nine clones yielded V
2 and V
4 products, two clones V
1 and V
2, two clones V
1, V
2 and V
4, and one clone V
4, while no clones yielded V
5, V
6, or V
7 products (Table 1). There was no distinctive difference in the usage of V
by Lyt-2+ clones from that by DN clones. All of 12 clones with RT-PCR V
4 products reacted with an antibody specific to V
4 in the flow cytometric analysis, indicating that V
4 chains were indeed expressed on the cell surface. It has been reported that the V
4 chain is preferentially used by thymus-dependent 
T cells, while V
1 and V
2 chains are used by both thymus-dependent and -independent 
T cells (26, 27). Thus, the results indicated that most, if not all, of these clones were derived from adult thymus. To determine the diversity in the CDR3 region of
chains, RT-PCR products from seven representative clones, three Lyt-2+ and four DN, were sequenced (Fig. 6). One or two in-frame products were identified and they contained N region nucleotides at all the V–J junctions except for V
2 and V
4 chains in KC1-3 and KC4-8, respectively. The deduced amino acid sequences for the CDR3 were different from one another except for those of the V
2 chains in the KC6-1 and KC7-4 clones, suggesting that a diverse set of 
TCR recognize the TL molecule. In summary, the usage of V
4 chains with N sequences in 12 of 14 clones, and the expression of Thy-1, Ly-1, and CD8
β heterodimer in the case of Lyt-2+ clones, indicated that these 
CTL clones that recognize TL were matured in adult thymus.
|
| Discussion |
|---|
|
|
|---|

T cells, in contrast to those in C3H mice which were found to be mostly
β T cells. Most of the 
CTL were of adult thymic origin; all of them expressed Thy-1, Ly-1 (CD5) and CD8
β heterodimers in the cases of Lyt-2+ clones, and 12 of 14 clones used TCR V
4 chains with N sequences in the V–J junctions except for V
4 of KC4-8. Thus, our results indicate that the presence of Tlaa-3-TL in the thymus promotes the positive selection of 
T cells recognizing T3b-TL. T3b and Tlaa-3 have identical amino acids in the putative PBR which determine the binding specificity to antigenic peptides and to TCR. Therefore, it is most likely that 
T cells, selected on the basis of their affinity for Tlaa-3, are able to react with T3b as well, and that such 
T cells are stimulated to generate CTL against T3b by T3b+ skin grafts. Thus, the presence of TL molecules in the thymus is required for the selection of 
T cells reactive to TL, and cannot be substituted for by any other MHC class I or CD1 molecules expressed in C3H mice. This notion is supported by the expansion of 
T cells in the thymus and periphery of the other transgenic mouse strain, Tg.Tlaa-3-1, as we reported previously (13). An association of TL antigen with 
T cells has also been speculated from the observation that it is expressed in the intestinal epithelium and 
T cells are present nearby (9, 10), although no direct evidence for any interaction between the intestinal epithelium and 
T cells has been presented.
It is an intriguing question whether normal mice that express TL in the thymus also produce 
CTL with specificity for TL. However, they do have at least two, and as many as four, TL genes (6, 31) which are expressed simultaneously in the thymus at levels which differ from strain to strain. Therefore, it will be a very difficult task to determine which TL genes are responsible for T3b-specific responses and for selection of 
CTL. Although two TL congenic strains, B6-TL+ and A-TL– are available, it is known that they are different from their counterparts, B6 and A, not only in terms of their TL genes but also for as many as 20 other MHC class I genes located in the TL region (32). Some of these class I genes have very similar structures and expression patterns to TL genes (10, 32), and some have been shown to cause skin graft rejection (33). Accordingly, it will be very difficult to rule out their involvement in TL recognition. To unravel the complexity of the TL system, we have generated and analyzed transgenic mice with Tlaa-3 gene driven by its own promoter as a first step. A definite answer can only be obtained from the analysis of transgenic mice with other TL genes, such as Tlaa-1, Tlaa-2 and T18d, which are currently under construction.
Regarding the specificity, the finding that both bulk and cloned 
CTL were cytotoxic against Tlaa-3-expressing RADA1 suggested that they may be auto-reactive. RADA1, however, expresses at least two other TL genes, in addition to Tlaa-3 (6). Thus, there remains a possibility that the reactivity is directed against antigens encoded by TL genes other than Tlaa-3. To clarify this point, target cells expressing only Tlaa-3 are needed. Transfection experiments to this end are now underway. Only after they are concluded and modes of recognition of TL molecules by CTL are elucidated (see below), will we be in a position to answer the questions of whether and how the negative selection operates against Tlaa-3 in the thymus.
The majority of 
T cells in mice and humans and most 
T cell clones or hybridomas reported so far do not express either CD4 or CD8 (4, 5). This suggests that 
T cells recognize MHC or non-MHC molecules with low or no affinity to CD4 or CD8 coreceptors, or that the maturation and activation of 
T cells do not require the presence of CD4 or CD8 molecules. Since there have hitherto been only few reports of 
T cell clones with clear CTL or helper activity, it has been difficult to conduct detailed studies on the requirement of coreceptors for 
T cells. Our present finding that 8 of 14 TL-restricted 
CTL clones express CD8
β, supports the proposal that TL can bind CD8 (34) and further implies that the CD8-p56lck signal pathway can operate in 
CTL, similarly to the
β CTL case (35). In addition to CD8+ 
CTL, DN 
CTL clones were also established. Analysis of DN 
CTL clones has so far shown no differences from CD8+ 
CTL clones in their cytotoxic specificity or activity, or in the expression of costimulatory or adhesion molecules except CD8. The differential expression of CD8 in these 
CTL may be due to the affinity of TCR for the target, or to the density of antigenic epitopes. Measurement of the affinity of TCR
expressed in CD8+ and DN CTL clones, and detailed analysis of the target molecules of these 
CTL, are now needed to clarify these issues.
Most of our sequenced 
CTL clones were found to have two in-frame TCR
chain transcripts. Further studies with transgenic mice are needed to determine which inframe
chain is responsible for TL recognition, although surface expression of the V
2 chain is in doubt (30, 36). It has been speculated that the TL molecule, a member of the nonpolymorphic MHC class I molecules, may be recognized by a limited set of TCR (37). However, this seems to be unlikely since the present analysis showed diversity in the CDR3 region of
chains, although analysis of
chains is still necessary. The results suggest heterogeneity in antigenic epitopes and TL recognition by CTL as discussed below.
Tlaa-3, T3k, and T3b have identical amino acid sequences in their PBRs. In their whole proteins, however, Tlaa-3 and T3b differ at over 30 amino acid positions, while T3k and T3b are different at a single amino acid position, 276 in the transmembrane region (Fig. 1). T3k expressed in the intestine of C3H and Tlaa-3 transgenic mice may not have any significance for the recognition of T3b, since a previous experiment suggested that T3b expressed in the intestine does not induce tolerance against T3b itself expressed in the skin (12). Identification of the antigenic epitopes recognized by 
and
β CTL against TL should reveal antigenic determinant(s) responsible for skin graft rejection. The CTL against TL were all TL-restricted, regardless of the C3H or Tg.Tlaa-3-2 origin and usage of TCR
β or TCR
. There are several possible modes in which CTL can recognize TL molecules. For example, CTL may recognize a complex of TL and endogenous peptides, similar to conventional CTL recognition of classical MHC molecules (38), or a complex of TL and nonpeptide antigens such as CD1 plus lipids (39). CTL may interact with TL molecules without any contribution from bound peptides, possibly from the side of the TL molecule, away from the putative PBR of the
1 and
2 domains (40), or with a complex of TL molecules and peptides derived from TL itself. The CTL may be heterogeneous in TL recognition; some CTL may recognize TL + peptides while others may recognize TL itself. To determine how TL molecules are recognized by CTL, the established CTL clones will be tested further on various TL+ target cells including transfectants of Drosophila melanogaster cells expressing TL molecules devoid of binding endogenous peptides (41). Recent studies using a TAP-2–deficient cell line, RMA-S, have demonstrated that the transport of TL molecules to the cell surface is TAP-2 independent (31, 42), but these findings do not necessarily exclude the possibility that TL molecules bind antigenic peptides by other mechanisms. Our previous structural comparison of TL antigens with classical class I antigens suggested that TL molecules can form peptide-binding clefts (37). There has been a report that they bind to peptides modified at the amino termini (43), although an absence of peptides bound to TL has been also reported (42). The CTL assay is by far the most sensitive method for detecting antigenic peptides bound to MHC molecules (44), and its application should allow more complete elucidation of the function of TL in the immune system.
| Acknowledgments |
|---|
Submitted: 24 June 1996
Revised: 17 September 1996
1Abbreviations used in this paper: B6, C57BL/6; C3H, C3H/He; cAb, conventional antibody; DN, CD4–CD8– double negative; Ltk–, thymidine kinase-negative L cell; MFI, mean fluorescence intensity; PBR, peptide binding region; RT, reverse transcription.
| References |
|---|
|
|
|---|
1 Klein, J. 1986. Natural History of the Major Histocompatibility Complex. John Wiley & Sons, Inc., New York. 775 pp.
2 Shawar SM, Vyas JM, Rodgers JR & Rich RR. Antigen presentation by major histocompatibility complex class I-Bmolecules, Annu Rev Immunol, 1994, 12, 839–880.[Medline]
3 Simister NE & Mostov KE. An Fc receptor structurally related to MHC class I antigens, Nature (Lond), 1989, 337, 184–187.[Medline]
4 Haas W, Pereira P & Tonegawa S. Gamma/delta cells, Annu Rev Immunol, 1993, 11, 637–685.[Medline]
5 Bluestone JA, Khattri R, Sciammas R & Sperling AI. TCR
cells: a specialized T-cell subset in the immune system, Annu Rev Cell Dev Biol, 1995, 11, 307–353.[Medline]
6 Chen Y-T, Obata Y, Stockert E, Takahashi T & Old LJ. Tla-region genes and their products, Immunol Res, 1987, 6, 30–45.[Medline]
7 Old LJ & Stockert E. Immunogenetics of cell surface antigens of mouse leukemia, Annu Rev Genet, 1977, 11, 127–160.[Medline]
8 Boyse EA, Old LJ & Luell S. Antigenic properties of experimental leukemias. II. Immunological studies in vivowith C57BL/6 radiation–induced leukemias, J Natl Cancer Inst, 1963, 31, 987–995.
9 Hershberg R, Eghtesady P, Sydora B, Brorson K, Cheroutre H, Modlin R & Kronenberg M. Expression of the thymus leukemia antigen in mouse intestinal epithelium, Proc Natl Acad Sci USA, 1990, 87, 9727–9731.
10 Wu M, Van Kaer L, Itohara S & Tonegawa S. Highly restricted expression of the thymus leukemia antigens on intestinal epithelial cells, J Exp Med, 1991, 174, 213–218.
11 Hamasima N, Takahashi T, Taguchi O, Nishizuka Y, Stockert E, Old LJ & Obata Y. Expression of TL, H-2, and chimeric H-2/TL genes in transgenic mice: abnormal thymic differentiation and T-cell lymphomas in a TL transgenic strain, Proc Natl Acad Sci USA, 1989, 86, 7995–7999.
12 Morita A, Takahashi T, Stockert E, Nakayama E, Tsuji T, Matsudaira Y, Old LJ & Obata Y. TL antigen as a transplantation antigen recognized by TL-restricted cytotoxic T cells, J Exp Med, 1994, 179, 777–784.
13 Obata Y, Taguchi O, Matsudaira Y, Hasegawa H, Hamasima N & Takahashi T. Abnormal thymic development, impaired immune function and 
T cell lymphomas in a TL transgenic mouse strain, J Exp Med, 1991, 174, 351–362.
14 Obata Y, Chen Y-T, Stockert E & Old LJ. Structural analysis of TLgenes of the mouse, Proc Natl Acad Sci USA, 1985, 82, 5475–5479.
15 Chen Y-T, Obata Y, Stockert E & Old LJ. Thymus-leukemia (TL) antigens of the mouse. Analysis of TL mRNA and TL cDNA from TL+ and TL–strains, J Exp Med, 1985, 162, 1134–1148.
16 Ledbetter JA & Herzenberg LA. Xenogeneic monoclonal antibodies to mouse lymphoid differentiation antigens, Immunol Rev, 1979, 47, 63–90.[Medline]
17 Dialynas DP, Quan ZS, Wall KA, Pierres A, Quintáns J, Loken MR, Pierres M & Fitch FW. Characterization of the murine T cell surface molecule, designated L3T4, identified by monoclonal antibody GK1.5: similarity of L3T4 to the human Leu-3/T4 molecule, J Immunol, 1983, 131, 2445–2451.[Abstract]
18 Kubo RT, Born W, Kappler JW, Marrack P & Pigeon M. Characterization of a monoclonal antibody which detects all murine
β T cell receptors, J Immunol, 1989, 142, 2736–2742.[Abstract]
19 Itohara S, Nakanishi N, Kanagawa O, Kubo R & Tonegawa S. Monoclonal antibodies specific to native murine T-cell receptor 
: analysis of 
T cells during thymic ontogeny and in peripheral lymphoid organs, Proc Natl Acad Sci USA, 1989, 86, 5094–5098.
20 Leo O, Foo M, Sachs DH, Samelson LE & Bluestone JA. Identification of a monoclonal antibody specific for a murine T3 polypeptide, Proc Natl Acad Sci USA, 1987, 84, 1374–1378.
21 Takagaki Y, DeCloux A, Bonneville M & Tonegawa S. Diversity of 
T-cell receptors on murine intestinal intraepithelial lymphocytes, Nature (Lond), 1989, 339, 712–714.[Medline]
22 Reilly EB, Kranz DM, Tonegawa S & Eisen HN. A functional
gene formed from known
-gene segments is not necessary for antigen-specific responses of murine cytotoxic T lymphocytes, Nature (Lond), 1986, 321, 878–880.[Medline]
23 Guy-Grand D, Cerf-Bensussan N, Malissen B, Malassis-Seris M, Briottet C & Vassalli P. Two gut intraepithelial CD8+lymphocyte populations with different T cell receptors: a role for the gut epithelium in T cell differentiation, J Exp Med, 1991, 173, 471–481.
24 Lefrancois L. Phenotypic complexity of intraepithelial lymphocytes of the small intestine, J Immunol, 1991, 147, 1746–1751.[Abstract]
25 Bandeira A, Itohara S, Bonneville M, Burlen-Defranoux O, Mota-Santos T, Coutinho A & Tonegawa S. Extrathymic origin of intestinal intraepithelial lymphocytes bearing T-cell antigen receptor 
, Proc Natl Acad Sci USA, 1991, 88, 43–47.
26 Pereira P, Gerber D, Huang SY & Tonegawa S. Ontogenic development and tissue distribution of V
1expressing
/
T lymphocytes in normal mice, J Exp Med, 1995, 182, 1921–1930.
27 Whetsell M, Mosley RL, Whetsell L, Schaefer FV, Miller KS & Klein JR. Rearrangement and junctionalsite sequence analyses of T-cell receptor gamma genes in intestinal intraepithelial lymphocytes from murine athymic chimeras, Mol Cell Biol, 1991, 11, 5902–5909.
28 Iwamoto A, Rupp F, Ohashi PS, Walker CL, Pircher H, Joho R, Hengartner H & Mak TW. T cell-specific
genes in C57BL/10 mice. Sequence and expression of new constant and variable region genes, J Exp Med, 1986, 163, 1203–1212.
29 Lafaille JJ, DeCloux A, Bonneville M, Takagaki Y & Tonegawa S. Junctional sequences of T cell receptor 
genes: implications for 
T cell lineages and for a novel intermediate of V-(D)-J joining, Cell, 1989, 59, 859–870.[Medline]
30 Pereira P, Gerber D, Regnault A, Huang SY, Hermitte V, Coutinho A & Tonegawa S. Rearrangement and expression of V
1, V
2 and V
3 TCR
genes in C57BL/6 mice, Int Immunol, 1996, 8, 83–90.
31 Rodgers JR, Mehta V & Cook RG. Surface expression of β2-microglobulin–associated thymus-leukemia antigen is independent of TAP2, Eur J Immunol, 1995, 25, 1001–1007.[Medline]
32 Steinmetz M, Winoto A, Minard K & Hood L. Clusters of genes encoding mouse transplantation antigens, Cell, 1982, 28, 489–498.[Medline]
33 Boyse EA, Flaherty L, Stockert E & Old LJ. Histocompatibility attributable to genes near H-2that are not revealed by hemagglutination or cytotoxicity tests, Transplantation (Baltimore), 1972, 13, 431–432.[Medline]
34 Teitell M, Mescher MF, Olson CA, Littman DR & Kronenberg M. The thymus leukemia antigen binds human and mouse CD8, J Exp Med, 1991, 174, 1131–1138.
35 Anderson SJ, Levin SD & Perlmutter RM. Involvement of the protein tyrosine kinase p56lckin T cell signaling and thymocyte development, Adv Immunol, 1994, 56, 151–178.[Medline]
36 Takagaki Y, Nakanishi N, Ishida I, Kanagawa O & Tonegawa S. T cell receptor-
and -
genes preferentially utilized by adult thymocytes for the surface expression, J Immunol, 1989, 142, 2112–2121.[Abstract]
37 Obata Y, Satta Y, Moriwaki K, Shiroishi T, Hasegawa H, Takahashi T & Takahata N. Structure, function, and evolution of mouse TLgenes, nonclassical class I genes of the major histocompatibility complex, Proc Natl Acad Sci USA, 1994, 91, 6589–6593.
38 Townsend A & Bodmer H. Antigen recognition by class I–restricted T lymphocytes, Annu Rev Immunol, 1989, 7, 601–624.[Medline]
39 Beckman EM, Porcelli SA, Morita CT, Behar SM, Furlong ST & Brenner MB. Recognition of a lipid antigen by CD1-restricted
β+T cells, Nature (Lond), 1994, 372, 691–694.[Medline]
40 Schild H, Mavaddat N, Litzenberger C, Ehrich EW, Davis MM, Bluestone JA, Matis L, Draper RK & Chien Y-H. The nature of major histocompatibility complex recognition by 
T cells, Cell, 1994, 76, 29–37.[Medline]
41 Jackson MR, Song ES, Yang Y & Peterson PA. Empty and peptide-containing conformers of class I major histocompatibility complex molecules expressed in Drosophila melanogastercells, Proc Natl Acad Sci USA, 1992, 89, 12117–12121.
42 Holcombe HR, Castaño AR, Cheroutre H, Teitell M, Maher JK, Peterson PA & Kronenberg M. Nonclassical behavior of the thymus leukemia antigen: peptide transporter–independent expression of a nonclassical class I molecule, J Exp Med, 1995, 181, 1433–1443.
43 Sharma P, Joyce S, Chorney KA, Griffith JW, Bonneau RH, Wilson FD, Johnson CA, Flavell RA & Chorney MJ. Thymus-leukemia antigen interacts with T cells and self-peptides, J Immunol, 1996, 156, 987–996.[Abstract]
44 Joyce S & Nathenson SG. Methods to study peptides associated with MHC class I molecules, Curr Opin Immunol, 1994, 6, 24–31.[Medline]
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| TABLE OF CONTENTS |
|